Blazing a new TRAIL in hematopoietic cell transplantation
Nelson Chao
Nelson Chao
Published May 15, 2013
Citation Information: J Clin Invest. 2013;123(6):2362-2363. https://doi.org/10.1172/JCI69909.
View: Text | PDF
Commentary

Blazing a new TRAIL in hematopoietic cell transplantation

Abstract

There is a ying/yang to most biological therapies, and the balance of efficacy versus toxicity is delicate and sometimes difficult to achieve in favor of the patients. When the therapeutic window is wide, these therapies can be used in the majority of patients, but when the therapeutic window is narrow, the decision to proceed must be carefully balanced with a thoughtful risk-benefit analysis. In this issue of the JCI, Ghosh et al. tackle one of the major obstacles in hematopoietic cell transplantation (HCT) technology: balancing the beneficial antitumor effect with the harmful anti-host effect.

Authors

Nelson Chao

×

Figure 1

The promise of TRAIL+ T cells in allo-HCT.

Options: View larger image (or click on image) Download as PowerPoint
The promise of TRAIL+ T cells in allo-HCT. The new sheriff (TRAIL+ T c...
The new sheriff (TRAIL+ T cells) kill off DR5+ cells while sparing other T cells, thus achieving the prevention of GVHD without loss of GVL.